What is the recommended dosing regimen for Paxlovid (nirmatrelvir/ritonavir)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Paxlovid (Nirmatrelvir/Ritonavir) Dosing Regimen

The standard recommended dosage for Paxlovid is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) taken together orally twice daily for 5 days. 1

Standard Dosing Protocol

  • Paxlovid should be initiated as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset 1
  • The complete 5-day treatment course should be taken to maximize viral clearance and minimize transmission 1
  • All three tablets (two nirmatrelvir 150 mg tablets plus one ritonavir 100 mg tablet) should be taken together twice daily, in the morning and at bedtime 1
  • Paxlovid can be taken with or without food 1
  • Tablets should be swallowed whole and not chewed, broken, or crushed 1

Dosage Adjustments for Special Populations

Renal Impairment

  • No dosage adjustment needed for mild renal impairment (eGFR ≥60 to <90 mL/min) 1
  • For moderate renal impairment (eGFR ≥30 to <60 mL/min): 150 mg nirmatrelvir (one tablet) with 100 mg ritonavir (one tablet) twice daily for 5 days 1, 2
  • For severe renal impairment (eGFR <30 mL/min) including patients requiring hemodialysis 1:
    • Day 1: 300 mg nirmatrelvir (two tablets) with 100 mg ritonavir (one tablet) once
    • Days 2-5: 150 mg nirmatrelvir (one tablet) with 100 mg ritonavir (one tablet) once daily
    • For hemodialysis patients, administer dose after hemodialysis 1

Hepatic Impairment

  • No dosage adjustment needed for mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment 1
  • Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C) 1

Important Clinical Considerations

  • Ritonavir is a strong CYP3A inhibitor and can cause significant drug-drug interactions 3, 4
  • Always check for drug interactions before prescribing Paxlovid using resources like the Liverpool COVID-19 Drug Interaction Tool 3, 4
  • High-risk interactions to avoid include certain antiarrhythmics, anticoagulants, and statins 4
  • The duration of interaction risk extends beyond the 5-day treatment period due to ritonavir's effects on metabolism and clearance 4
  • Common adverse effects include dysgeusia (altered taste) and diarrhea 3, 1

Missed Dose Management

  • If a dose is missed within 8 hours of the scheduled time: take it as soon as possible and resume normal schedule 1
  • If a dose is missed by more than 8 hours: skip the missed dose and take the next dose at the regularly scheduled time 1
  • Do not double the dose to make up for a missed dose 1

Pharmacokinetic Considerations

  • Nirmatrelvir is primarily eliminated by the kidneys when co-administered with ritonavir 5, 2
  • Ritonavir inhibits nirmatrelvir's CYP3A4-mediated metabolism, increasing its plasma concentration and extending its half-life 5
  • When properly dosed with ritonavir, nirmatrelvir reaches concentrations well above the antiviral effective concentration (EC90) 5

Paxlovid has shown significant efficacy in reducing hospitalization and death in high-risk COVID-19 patients when administered within the recommended timeframe 3, 6. Careful attention to dosing adjustments based on renal function and potential drug interactions is essential for safe and effective treatment.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.